Gilead Announces Positive Phase 3 HCV Treatment Results in Patients Co-Infected With HIV
November 02, 2013 at 17:15 PM EDT
Gilead Sciences (NASDAQ: GILD ) today announced results from a Phase 3 study, PHOTON-1, evaluating the investigational once-daily nucleotide analogue sofosbuvir for the treatment of chronic hepatitis C virus (HCV)
